AstraZeneca Wins With Concentration On Rural China
This article was originally published in PharmAsia News
Executive Summary
U.K.-based AstraZeneca has developed a different China strategy than most of its global competitors in the drug-making business. Instead of concentrating on a quest for big sales in the largest of China's cities, AstraZeneca has been working on sales in more rural parts of the country ignored by competitors. The firm's sales in China about quintupled since 2001, with sales last year amounting to $423 million, making it No. 1 in the Chinese market. That domination could add leverage for AstraZeneca as it seeks to expand its share of the lucrative Chinese market. (Click here for more - a subscription may be required
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.